SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potentialNovel JAK2 V617F ...

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for PROTAC BCL6 degrader ...

Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, ...

The mission of our ACGME-accredited fellowship is to provide an environment to develop the next generation of leaders in the fields of hematology and oncology. By utilizing resources and mentors ...

Two presentations, including one oral session, build on existing data and show deep and durable clinical remission rates, combined with a strong safety profile, for SENTI-202 in treating ...

Title: A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study ...

The Division of Hematology-Oncology at Baylor College of Medicine is one of the largest and most comprehensive academic programs of its kind in the world. Faculty in the division provide care through ...

Patients can now receive services at the University of Michigan Health-West's new Hematology and Cancer Care building in ...